Constitutively Active Androgen Receptor Variants Upregulate Expression of Mesenchymal Markers in Prostate Cancer Cells

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Cottard, Félicie ^a   Asmane, Irène ^a,b   Erdmann, Eva ^a   Bergerat, Jean Pierre ^a,b   Kurtz, Jean Emmanuel ^a,b   Céraline, Jocelyn ^a,b  

^a UNIVERSITÉ DE STRASBOURG   (France)

^b UNIVERSITY HOSPITAL OF STRASBOURG   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; NERVE CELL ADHESION MOLECULE; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR ZEB1; VIMENTIN;

ARTICLE; CANCER CELL; CASTRATION RESISTANT PROSTATE CANCER; CELL SELECTION; CONTROLLED STUDY; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; MESENCHYME CELL; MOLECULAR DYNAMICS; PLASMID; PROTEIN EXPRESSION; PROTEIN MODIFICATION; UPREGULATION; WESTERN BLOTTING;

CADHERINS; CELL LINE, TUMOR; DISEASE PROGRESSION; GENETIC VARIATION; HOMEODOMAIN PROTEINS; HUMANS; MALE; MESODERM; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION; VIMENTIN;

EID: 84877048131     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0063466     Document Type: Article

References (41)

1. Cunha GR, Ricke W, Thomson A, Marker PC, Risbridger G, et al. (2004) Hormonal, cellular, and molecular regulation of normal and neoplastic prostatic development. J Steroid Biochem Mol Biol 92: 221-236.
2. Ceraline J, Cruchant MD, Erdmann E, Erbs P, Kurtz JE, et al. (2004) Constitutive activation of the androgen receptor by a point mutation in the hinge region: a new mechanism for androgen-independent growth in prostate cancer. Int J Cancer 108: 152-157.
3. Lapouge G, Erdmann E, Marcias G, Jagla M, Monge A, et al. (2007) Unexpected paracrine action of prostate cancer cells harboring a new class of androgen receptor mutation - a new paradigm for cooperation among prostate tumor cells. Int J Cancer 121: 1238-1244.
4. Marcias G, Erdmann E, Lapouge G, Siebert C, Barthelemy P, et al. (2010) Identification of novel truncated androgen receptor (AR) mutants including unreported pre-mRNA splicing variants in the 22Rv1 hormone-refractory prostate cancer (PCa) cell line. Hum Mutat 31: 74-80.
5. Bergerat JP, Ceraline J, (2009) Pleiotropic functional properties of androgen receptor mutants in prostate cancer. Hum Mutat 30: 145-157.
6. Dehm SM, Schmidt LJ, Heemers HV, Vessella RL, Tindall DJ, (2008) Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res 68: 5469-5477.
7. Guo Z, Yang X, Sun F, Jiang R, Linn DE, et al. (2009) A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res 69: 2305-2313.
8. Hornberg E, Ylitalo EB, Crnalic S, Antti H, Stattin P, et al. (2011) Expression of Androgen Receptor Splice Variants in Prostate Cancer Bone Metastases is Associated with Castration-Resistance and Short Survival. PLoS One 6: e19059.
9. Hu R, Dunn TA, Wei S, Isharwal S, Veltri RW, et al. (2009) Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res 69: 16-22.
10. Watson PA, Chen YF, Balbas MD, Wongvipat J, Socci ND, et al. (2010) Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci U S A 107: 16759-16765.
11. Li Y, Chan SC, Brand LJ, Hwang TH, Silverstein KA, et al. (2013) Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Cancer Res 73: 483-489.
12. Mostaghel EA, Marck BT, Plymate SR, Vessella RL, Balk S, et al. (2011) Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res 17: 5913-5925.
13. Lapouge G, Marcias G, Erdmann E, Kessler P, Cruchant M, et al. (2008) Specific properties of a C-terminal truncated androgen receptor detected in hormone refractory prostate cancer. Adv Exp Med Biol 617: 529-534.
14. Derycke LD, Bracke ME, (2004) N-cadherin in the spotlight of cell-cell adhesion, differentiation, embryogenesis, invasion and signalling. Int J Dev Biol 48: 463-476.
15. Gumbiner BM, (2005) Regulation of cadherin-mediated adhesion in morphogenesis. Nat Rev Mol Cell Biol 6: 622-634.
16. Kalluri R, (2009) EMT: when epithelial cells decide to become mesenchymal-like cells. J Clin Invest 119: 1417-1419.
17. Polyak K, Weinberg RA, (2009) Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 9: 265-273.
18. Voulgari A, Pintzas A, (2009) Epithelial-mesenchymal transition in cancer metastasis: mechanisms, markers and strategies to overcome drug resistance in the clinic. Biochim Biophys Acta 1796: 75-90.
19. Tomita K, van Bokhoven A, van Leenders GJ, Ruijter ET, Jansen CF, et al. (2000) Cadherin switching in human prostate cancer progression. Cancer Res 60: 3650-3654.
20. Clarke NW, Hart CA, Brown MD, (2009) Molecular mechanisms of metastasis in prostate cancer. Asian J Androl 11: 57-67.
21. Jin JK, Dayyani F, Gallick GE, (2011) Steps in prostate cancer progression that lead to bone metastasis. Int J Cancer 128: 2545-2561.
22. Jennbacken K, Tesan T, Wang W, Gustavsson H, Damber JE, et al. (2010) N-cadherin increases after androgen deprivation and is associated with metastasis in prostate cancer. Endocr Relat Cancer 17: 469-479.
23. Tanaka H, Kono E, Tran CP, Miyazaki H, Yamashiro J, et al. (2010) Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance. Nat Med 16: 1414-1420.
24. Sun Y, Wang BE, Leong KG, Yue P, Li L, et al. (2012) Androgen deprivation causes epithelial-mesenchymal transition in the prostate: implications for androgen-deprivation therapy. Cancer Res 72: 527-536.
25. Guyader C, Ceraline J, Gravier E, Morin A, Michel S, et al. (2012) Risk of hormone escape in a human prostate cancer model depends on therapy modalities and can be reduced by tyrosine kinase inhibitors. PLoS One 7: e42252.
26. Gustavsson H, Welen K, Damber JE, (2005) Transition of an androgen-dependent human prostate cancer cell line into an androgen-independent subline is associated with increased angiogenesis. Prostate 62: 364-373.
27. Jennbacken K, Gustavsson H, Welen K, Vallbo C, Damber JE, (2006) Prostate cancer progression into androgen independency is associated with alterations in cell adhesion and invasivity. Prostate 66: 1631-1640.
28. Takayama K, Kaneshiro K, Tsutsumi S, Horie-Inoue K, Ikeda K, et al. (2007) Identification of novel androgen response genes in prostate cancer cells by coupling chromatin immunoprecipitation and genomic microarray analysis. Oncogene 26: 4453-4463.
29. Alexander NR, Tran NL, Rekapally H, Summers CE, Glackin C, et al. (2006) N-cadherin gene expression in prostate carcinoma is modulated by integrin-dependent nuclear translocation of Twist1. Cancer Res 66: 3365-3369.
30. de Herreros AG, Peiro S, Nassour M, Savagner P, (2010) Snail family regulation and epithelial mesenchymal transitions in breast cancer progression. J Mammary Gland Biol Neoplasia 15: 135-147.
31. Escriva M, Peiro S, Herranz N, Villagrasa P, Dave N, et al. (2008) Repression of PTEN phosphatase by Snail1 transcriptional factor during gamma radiation-induced apoptosis. Mol Cell Biol 28: 1528-1540.
32. Kajita M, McClinic KN, Wade PA, (2004) Aberrant expression of the transcription factors snail and slug alters the response to genotoxic stress. Mol Cell Biol 24: 7559-7566.
33. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, et al. (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133: 704-715.
34. Morel AP, Lievre M, Thomas C, Hinkal G, Ansieau S, et al. (2008) Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS One 3: e2888.
35. McKeithen D, Graham T, Chung LW, Odero-Marah V, (2010) Snail transcription factor regulates neuroendocrine differentiation in LNCaP prostate cancer cells. Prostate 70: 982-992.
36. Tiwari N, Meyer-Schaller N, Arnold P, Antoniadis H, Pachkov M, et al. (2013) Klf4 Is a Transcriptional Regulator of Genes Critical for EMT, Including Jnk1 (Mapk8). PLoS One 8: e57329.
37. Berx G, van Roy F, (2009) Involvement of members of the cadherin superfamily in cancer. Cold Spring Harb Perspect Biol 1: a003129.
38. Hazan RB, Phillips GR, Qiao RF, Norton L, Aaronson SA, (2000) Exogenous expression of N-cadherin in breast cancer cells induces cell migration, invasion, and metastasis. J Cell Biol 148: 779-790.
39. Li G, Satyamoorthy K, Herlyn M, (2001) N-cadherin-mediated intercellular interactions promote survival and migration of melanoma cells. Cancer Res 61: 3819-3825.
40. Tran NL, Adams DG, Vaillancourt RR, Heimark RL, (2002) Signal transduction from N-cadherin increases Bcl-2. Regulation of the phosphatidylinositol 3-kinase/Akt pathway by homophilic adhesion and actin cytoskeletal organization. J Biol Chem 277: 32905-32914.
41. Nalla AK, Estes N, Patel J, Rao JS, (2011) N-cadherin mediates angiogenesis by regulating monocyte chemoattractant protein-1 expression via PI3K/Akt signaling in prostate cancer cells. Exp Cell Res 317: 2512-2521.